Agilent Technologies (A) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Jul, 2026Executive summary
Q4 revenue reached $1.86 billion, up 7.2% core and 9.4% reported, exceeding guidance and marking the sixth consecutive quarter of accelerating core growth.
Q4 non-GAAP EPS was $1.59, up 9% year-over-year and above the midpoint of guidance; GAAP EPS was $1.53, up 25%.
All business segments met or exceeded revenue expectations, with notable strength in LC/LCMS, CDMO, and robust performance in key regions.
The Ignite Operating System delivered over $150 million in annualized savings and improved organizational efficiency.
Integration of BIOVECTRA and leadership hires strengthened capabilities and future M&A readiness.
Financial highlights
Q4 core revenue growth was 7.2%, with reported growth at 9.4%; gross margin improved sequentially by 100 bps to 54.1%, though down 100 bps year-over-year due to tariffs.
Q4 operating margin was 27.2%, up over 200 bps sequentially, driven by volume leverage, pricing, and tariff mitigation.
Operating cash flow was $545 million in Q4; $93 million in capex, $85 million in share repurchases, and $70 million in dividends paid.
FY25 revenue totaled $6.95 billion, up 6.7% reported and 4.9% core, exceeding guidance.
Net leverage ratio ended at 0.8, reflecting a strong balance sheet.
Outlook and guidance
FY26 revenue expected at $7.3–$7.4 billion, representing 4%-6% core growth and 5%-7% reported; currency to be a 1% tailwind.
FY26 non-GAAP EPS guided to $5.86–$6.00, up 5%-7%, with a 3-point EPS headwind from higher tax rates.
Operating margin expansion of 75 bps expected, with 9% operating profit growth at midpoint.
Operating cash flow projected at $1.6–$1.7 billion; $500 million in capex planned.
Q1 FY26 revenue guided to $1.79–$1.82 billion (4%-6% core growth); Q1 EPS $1.35–$1.38.
Latest events from Agilent Technologies
- Enterprise transformation, margin growth, and specialty CDMO expansion drive 2026 outlook.A
Citi Annual Global Healthcare Conference 20259 Jul 2026 - Strong Q3 growth, margin recovery, and robust outlook driven by innovation and global demand.A
Wells Fargo 20th Annual Healthcare Conference 20258 Jul 2026 - Q2 revenue up 6% and non-GAAP EPS up 7%, with raised FY2025 outlook and operational gains.A
Q2 20258 Jul 2026 - Innovation, tech refresh, and AI initiatives fuel strong growth and margin expansion.A
Jefferies Global Healthcare Conference 20263 Jun 2026 - Q2 FY26 delivered double-digit revenue growth, margin expansion, and raised guidance.A
Q2 20261 Jun 2026 - Q1 FY26 revenue rose 7% to $1.8B, non-GAAP EPS up 4%, and FY26 guidance was raised.A
Q1 202614 Apr 2026 - siRNA manufacturing leadership drives growth in a $4B+ market with expanding capacity and innovation.A
Corporate presentation27 Mar 2026 - Strong growth, innovation, and disciplined strategy support positive outlook for the year.A
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Key votes include director elections, auditor ratification, and Board declassification.A
Proxy Filing6 Feb 2026